Docstoc

MolMed S.p.A. – Product Pipeline Review – H2 2011

Document Sample
MolMed S.p.A. – Product Pipeline Review – H2 2011 Powered By Docstoc
					MolMed S.p.A. – Product Pipeline Review – H2 2011

Summary

Global Market Direct pharmaceuticals report, “MolMed S.p.A. - Product Pipeline Review - H2
2011” provides data on the MolMed S.p.A. research and development focus. The report includes
information on current developmental pipeline, complete with latest updates, and features on
discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct proprietary
databases, MolMed S.p.A. corporate website, SEC filings, investor presentations and featured
press releases, both from MolMed S.p.A. and industry-specific third party sources, put together
by Global Markets Direct team.

Scope

- MolMed S.p.A. - Brief MolMed S.p.A. overview including business description, key
information and facts, and its locations and subsidiaries.
- Review of current pipeline of MolMed S.p.A. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the
combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of MolMed S.p.A. with complete
description of the product developmental history, mechanism of action, therapeutic class, target
and major milestones.
- Recent updates of the MolMed S.p.A. pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate MolMed S.p.A. strategic position with total access to detailed information on its
product pipeline.
- Assess the growth potential of MolMed S.p.A. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the MolMed S.p.A. R&D portfolio and
develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with MolMed S.p.A..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of MolMed S.p.A. and identify potential
opportunities in those areas.

For more information, please visit :-

Marketing Team

Aarkstore Enterprise

Phone:08149852585

Email:enquiry@aarkstore.com

URL:www.aarkstore.com

http://www.aarkstore.com/reports/MolMed-S-p-A-Product-Pipeline-Review-H2-2011-
161774.html

http://twitter.com/aarkstoredotcom

http://in.linkedin.com/in/aarkstore

http://www.facebook.com/aarkstoreenterprise

More Related Reports : -

Cell Therapeutics, Inc. – Product Pipeline Review – H2 2011
Spasticity - Pipeline Review, H2 2011
MolMed S.p.A. – Product Pipeline Review – H2 2011
Ocular Hypertension - Pipeline Review, H2 2011
Nereus Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011
Postherpetic Neuralgia - Pipeline Review, H2 2011
OncoTherapy Science, Inc. – Product Pipeline Review – H2 2011
Vaginal Atrophy - Pipeline Review, H2 2011
PLx Pharma Inc. – Product Pipeline Review – H2 2011
Thrombotic Thrombocytopenic Purpura - Pipeline Review, H2 2011

				
DOCUMENT INFO
Description: Aarkstore announce a new report " MolMed S.p.A. – Product Pipeline Review – H2 2011" through its vast collection of market research report